| 1 |
钱桂生. 肺癌不同病理类型发病率的变化情况及原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1):1-6.
|
| 2 |
Santarpia M, Liguori A, Karachaliou N, et al. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy[J]. Lung Cancer (Auckl), 2017, 8:109-125.
|
| 3 |
Wu H, Medeiros LJ, Young KH. Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances[J]. Blood Rev, 2017, doi: 10.1016/j.blre.2017.08.004. |
| 4 |
Karachaliou N, Rosell R, Molina MA, et al. Predicting resistance by selection of signaling pathways[J]. Transl Lung Cancer Res, 2014, 3(2):107-115.
|
| 5 |
Katagiri S, Umezu T, Ohyashiki JH, et al. The BCL2L11 (BIM) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patients[J]. Br J Haematol, 2013, 160(2):269-271.
|
| 6 |
Ng KP, Hillmer AM, Chuah CT, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer[J]. Nat Med, 2012, 18(4):521-528.
|
| 7 |
Richter-Larrea JA, Robles EF, Fresquet V, et al. Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma[J]. Blood, 2010，116(14):2531-2542.
|
| 8 |
Wang J, Zhou JY, Wu GS. Bim protein degradation contributes to cisplatin resistance[J]. J Biol Chem, 2011, 286(25):22384-22392.
|
| 9 |
Zhong J, Li ZX, Zhao J, et al. Analysis of BIM (BCL-2 like 11 gene) deletion polymorphism in Chinese Non-small cell lung cancer patients[J]. Thoracic Cancer, 2014, 5(6):509-516.
|
| 10 |
Eisenhauer EA, Thersasse P, Bogaerts J, et al. New respongse evaluation criteria in solid tumors: revised RECIST guideline [J]. Eur J Cancer, 2009, 45(2):228-247.
|
| 11 |
Trotti A, Bentzen SM. The need for adverse effects reporting standards in oncology clinical trials[J]. J Clin Oncol, 2004, 22(1):19-22.
|
| 12 |
吕洋，苗立云. 非小细胞肺癌分子靶向药物耐药机制的研究进展[J/CD]. 中华肺部疾病杂志(电子版), 2015, 8(1):82-84.
|
| 13 |
Bouillet P, Zhang LC, Huang DC, et al. Gene structure alternative splicing, and chromosomal localization of pro-apoptotic Bcl-2 relative Bim[J]. Mamm Genome, 2001, 12(2):163-168.
|
| 14 |
Hsu SY, Lin P, Hsueh AJ. BOD(Bcl-2-related ovarian death gene) is an ovarian BH3 domain-containing proapoptotic Bcl-2 protein capable of dimerization with diverse antiapoptotic Bcl-2 members[J]. Mol Endocrinol, 1998, 12(9):1432-1440.
|
| 15 |
Qian K, Zhang Y, Zhi X. Retrospective Study of Efficacy in BIM Gene Polymorphism on First-line EGFR-TKIs Treatment for Advanced Lung Adenocarcinoma[J]. Zhongguo Fei Ai Za Zhi, 2017, 20(8):543-548.
|
| 16 |
Cheng F, Pan Y, Lu YM, et al. RNA-Binding Protein Dnd1 Promotes Breast Cancer Apoptosis by Stabilizing the Bim mRNA in a miR-221 Binding Site[J]. Biomed Res Int, 2017, 2017:e9596152.
|
| 17 |
Kim KO, Hsu AC, Lee HG, et al. Proteomic identification of 14-3-3∈ as a linker protein between pERK1/2 inhibition and BIM upregulation in human osteosarcoma cells[J]. J Orthop Res, 2014, 32(6):848-854.
|
| 18 |
Gambichler T, Rooms I, Scholl L, et al. BH3-only protein Bim predicts advanced stage of cutaneous melanoma[J]. J Eur Acad Dermatol Venereol, 2016, 30(11):1926-1929.
|
| 19 |
Faber AC, Ebi H, Costa C, et al. Apoptotic in targeted therapy responses: the role of BIM[J]. Adv Pharmacol, 2012, 65:519-542.
|
| 20 |
Zou Q, Zhan P, Lv T, et al. The relationship between BIM deletion polymorphism and clinical significance of epidermal growth factor receptor-mutated non-small cell lung cancer patients with epidermal growth factor receptor-tyrosine kinase inhibitor therapy: a meta-analysis[J]. Transl Lung Cancer Res, 2015, 4(6):792-796.
|
| 21 |
Lee HY, Kim IK, Lee HI, et al. The apoptotic effect of simvastatin via the upregulation of BIM in nonsmall cell lung cancer cells[J]. Exp Lung Res, 2016, 42(1):14-23.
|
| 22 |
Ying HQ, Chen J, He BS, et al. The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy[J]. Sci Rep, 2015, 5:doi: 10.1038/srep11348. |
| 23 |
Kaufmann T, Jost PJ, Pellegrini M, et al. Fatal hepatitis mediated by tumor necrosis factor TNFalpha requires caspase-8 and involves the BH3-only proteins Bid and Bim[J]. Immunity, 2009, 30(1):56-66.
|
| 24 |
Willis SN, Adams JM. Life in the balance: how BH3-only proteins induce apoptosis[J]. Curr Opin Cell Biol, 2005, 17(6):617-625.
|
| 25 |
Costa DB, Halmos B, Kumar A, et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations[J]. PLoS Med, 2007, 4(10):1669-1679.
|
| 26 |
Gong Y, Somwar R, Politi K, et al. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR dependent lung adenocarcinomas[J]. PLoS Med, 2007, 4:e294.
|
| 27 |
Lee JH, Lin YL, Hsu WH, et al. BCL-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cance[J]J Thorac Oncol, 2014, 9(9):1385-1392.
|
| 28 |
Akiyama T, Dass CR, Choong PF. Bim-targeted cancer therapy：a link between drug action and unde rlying molecular changes[J]. Mol Cancer Ther, 2009, 8(12):3173-3180.
|
| 29 |
Wu YL, Saijo N, Thongprasert S, et al. Efficacy according to blind independent central review: Post-hoc analyses from the phase Ⅲ，randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC[J]. Lung Cancer, 2017, 104:119-125.
|
| 30 |
Wu YL, Fukuoka M, Mok TS, et al. Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study[J]. Lung Cancer, 2013, 81(2):280-287.
|
| 31 |
Xia JJ, Xiong LW, Chu TQ, et al. Association between BIM deletion polymorphism and the risk of non-small cell lung cancer in Chinese[J]. Int J Clin Exp Pathol, 2016, 9(5):5647-5655.
|
| 32 |
Sun S, Yu H, Wang H, et al. Exploratory cohort study and meta－analysis of BIM deletion polymorphism in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors[J]. Onco Targets Ther, 2017, 10:1955-1967.
|
| 33 |
Ma JY, Yan HJ, Gu W. Association between BIM deletion polymorphism and clinical outcome of EGFR-mutated NSCLC patient with EGFR-TKI therapy: A meta-analysis[J]. J Cancer Res Ther, 2015, 11(2):397-402.
|
| 34 |
Lee JH, Lin YL, Hsu WH, et al. Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer[J]. J Thorac Oncol, 2014, 9(9):1385-1392.
|